User:Tkadm30/Notebook/Endocannabinoids/Synopsis

Synopsis

• Stimulation of endocannabinoid transport with polyunsaturated (22:6n-3) fatty acids (DHA, EPA) to target major depressive disorders (MDD) , epilepsy, amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), posttraumatic stress disorder (PTSD), Parkinson's disease (PD), and Alzheimer's disease (AD).
• Distribution of endocannabinoid-dependent activity (LTP, synaptogenesis, CREB) in the hippocampus promoting brain-derived neurotrophic factor (BDNF) expression, a biological marker for learning-dependent synapse formation. PMID PMID
• Intracellular CB1 signaling mediate on-demand neuroprotection on excitatory (glutamatergic) synapses and in particular astrocytes. PMID PMID
  • DHA supplementation improves mitochondrial function and neuronal survival. PMID
• Identification of a functional GPR40-GPR55 receptor heteromer with potent anti-inflammatory, antiglutamatergic and neuroprotective properties.
  • Anti-proliferative effects of DHEA on prostate cancer cell lines. PMC
  • A synaptogenic endocannabinoid promoting synaptogenesis.
  • Antioxidant (cytoprotective) properties of GPR40-GPR55 heteromer.
• Effects of the endothelial CB2 receptor persistent activation on monocyte subpopulations/microglial activation PMID
  • Anti-inflammatory role of anandamide and 2-AG signaling in LPS-stimulated microglial activation of endogenous CB2 receptor. Link
  • Neuroprotection by inhibition of microglial activation. PMID PMID
  • CB2 stimulation is proneurogenic on adult hippocampal neurogenesis PMC
• Caffeine is a adenosine antagonist which mediate CB1 receptor activation in the hippocampus PMID PMID